BIPI Independent Medical Education Grant

Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) - BI Cares Foundation

Suggest an update

Grant amount: Unspecified amount

Deadline: Rolling

Applicant type: Organizations

Funding uses: Conference, Education / Outreach

Location of project: United States

Location of residency: United States

View website    Save Need help writing this grant?

About this funder:

Loading...

Overview:

Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) is proud to provide Independent Medical Education Grant support for specific independent educational activities for healthcare providers that may translate to better management of disease and improvement in patient safety and population health. An independent educational program may be at the national, regional or local level and may include but is not limited to, live and interactive didactic presentations (e.g., symposia at major educational meetings, grand rounds, regional workshops), web-based programs, print and electronic monographs and other innovative educational formats.

BIPI considers funding of activities both independently and through its alliance arrangement with Lilly USA, LLC (Lilly) in a variety of areas including:

BIPI Areas of Strategic Focus

Immunology

Dermatology

  • Improve HCP knowledge of identifying best practices for assessing disease severity and diagnosis of pustular psoriasis in adult patients.
  • Enhance HCP understanding of recent pathophysiological findings in pustular psoriasis, GPP, and PPP that have informed the selection of new therapeutic targets.
  • Educate HCPs on the clinical profiles and mechanisms of action of new and emerging agents for the treatment of adults with GPP and PPP.

Oncology

Non-Small Cell Lung Cancer (Limited Funding Available)

  • Increase clinicians’ understanding of the heterogeneity of disease among patients with NSCLC and the clinical impact of distinguishing between subpopulations (e.g. different histologies, different sub-types) to optimize therapeutic strategies.
  • Increase clinicians’ understanding of treating patients with EGFR positive NSCLC in the light of resistance mechanism after 1st line treatment with anti-EGFR agents.
  • Review the management of adverse events associated with the use of oral anti-EGFR agents.
  • Increase clinicians’ understanding of biology, incidence and treatment options for patients with NSCLC and uncommon EGFR mutations.
  • Increase clinicians’ awareness of Real World Data in patients with EGFR+ advanced NSCLC and its implications on patient management decisions.
  • Increase clinicians’ understanding of appropriate testing for advanced disease, emerging data on relevant genomic biomarkers and the changing treatment landscape in patients with metastatic squamous NSCLC.

Respiratory

Interstitial Lung Disease (ILD) 

  • Disease course, diagnosis and risk assessment: Increase clinicians’ understanding of disease prevalence, morbidity and mortality, burden of illness, and signs and symptoms of ILD (IPF, Connective Tissue Disease (CTD) related ILD). Additionally improve clinician’s knowledge of recommended diagnostic testing methods and interpretation (e.g. HRCT, surgical biopsy, serologic testing) and the importance of routine, comprehensive multidisciplinary assessments in patients with CTD-ILD.
  • Earlier identification and differentiation of ILDs: Raise the index of awareness of ILD among HCPs to encourage earlier referral of appropriate patients with ILD (IPF and Connective Tissue Disease related ILD) to ILD centers.
  • Treatment guidelines and clinical management: Improve clinicians’ knowledge regarding IPF clinical management, including developments in clinical research and treatment guidelines.
  • IPF risk factors and co-morbidities: Increase understanding among pulmonologists regarding management of the possible IPF risk factors (such as pharmacogenetics, pharmacogenomics) and co-morbidities for IPF (such as GERD), as well as the importance of managing other co-morbidities.
  • HCP communication with patients: Improve clinicians understanding of how to effectively communicate and educate ILD patients about their disease.

Systemic Sclerosis Interstitial Lung Disease (SSc-ILD)

  • Disease course, diagnosis and risk assessment: Increase clinicians’ understanding of disease pathophysiology, prevalence, morbidity and mortality and signs and symptom of SSc-ILD. Additionally improve clinician’s knowledge about the need to evaluate and monitor lung involvement in patients with SSc (e.g. HRCT scan, PFTs).
  • Treatment guidelines and clinical management: Improve clinicians’ knowledge regarding SSc-ILD clinical management, including developments in clinical research and treatment guidelines.
  • HCP communication with patients: Improve clinicians understanding of how to effectively communicate and educate SSc-ILD patients about their disease.

Interstitial Lung Diseases (ILDs) with Progressive Lung Disease Phenotype

  • Description of ILDs with Progressive Lung Disease Phenotype: Improve clinician’s knowledge about the diseases most commonly associated with ILDs with Progressive Lung Disease Phenotype (i.e. Rheumatoid Arthritis, Chronic Hypersensitivity Pneumonitis, Unclassified ILD) and the need to monitor lung involvement in patients with these diseases.
  • Disease course, diagnosis and assessment: Increase clinicians’ understanding of disease pathophysiology, prevalence, morbidity and mortality, and signs and symptoms of ILDs with Progressive Lung Disease Phenotype.
  • Clinical management: Improve clinicians’ knowledge regarding ILDs with Progressive Lung Disease Phenotype clinical management, including developments in clinical research and treatment guidelines.

BIPI/Lilly Alliance Therapeutic Areas

Therapeutic Areas of interest supported by the Boehringer Ingelheim Pharmaceutical Inc (BIPI) and Eli Lilly and Company (Lilly) global Alliance agreement: 

Educational Objectives - Diabetes 

  • Improve clinicians’ understanding of the current guidelines and scientific evidence supporting management of cardiovascular risk in patients with Type 2 diabetes
  • Improve clinicians’ understanding and knowledge of optimally managed benefit/risk profiles of treatments for patients with Type 1 Diabetes
  • Enhance clinicians' awareness and knowledge of emerging scientific evidence regarding treatment of patients with type 2 diabetes patients with or without concomitant heart failure or renal disease
  • To help improve the insulin experience for people with diabetes and increase clinicians’ understanding of the following:
    • Insulin Initiation Experience and Barriers
      • Insulin initiation experience, including the underlying causes of psychological insulin resistance
      • Adherence/Persistence
      • Impact of barriers on patient outcomes
    • Strategies supported by evidence to overcome aforementioned barriers, including emotional support

You can learn more about this opportunity by visiting the funder's website.

Eligibility:

  • A medical education grant must be designed to support independent medical education for healthcare providers and patients that may translate to better management of disease and improvement in patient safety and population health.
  • Grant applications must be submitted no less than 60 days prior to the program start date.